Tyrosine kinase activity of purified recombinant cytoplasmic domain of platelet-derived growth factor β-receptor (β-PDGFR) and discovery of a novel inhibitor of receptor tyrosine kinases

Biochemical Pharmacology

Volumn 57, Issue 1, 1999, Pages 57-64

  Zaman, Guido J R ^a   Vink, Paul M F ^a   Van den Doelen, Antoon A ^a   Veeneman, Gerrit H ^a   Theunissen, Henri J M ^a  

^a NV ORGANON   (Netherlands)

Author keywords

Fibroblast growth factor receptor; Growth factor receptor tyrosine kinase inhibitors; Platelet derived growth factor receptor; Tyrosine kinase; Vascular smooth muscle cells

Indexed keywords

3 (4 DIMETHYLAMINO BENZYLIDENYL) 2 INDOLINONE; BENZYLIDENE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE P60; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CARDIOVASCULAR DISEASE; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN PURIFICATION; RAT; RECEPTOR UPREGULATION; RESTENOSIS; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; SQUAMOUS CELL CARCINOMA;

3T3 CELLS; ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CELL LINE; CYTOPLASM; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GROWTH SUBSTANCES; HUMANS; INDOLES; KINETICS; MICE; MUSCLE, SMOOTH, VASCULAR; PHOSPHORYLATION; PHOSPHOTYROSINE; PLATELET-DERIVED GROWTH FACTOR; PULMONARY ARTERY; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECOMBINANT PROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0032945973     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00271-8     Document Type: Article

References (36)

1. Raines E.W., Ross R. Platelet-derived growth factor in vivo. Cytokines. 5:1993;74-114.
2. Claesson-Welsh L. Platelet-derived growth factor receptor signals. J Biol Chem. 269:1994;32023-32026.
3. Heldin C.-H. Dimerization of cell surface receptors in signal transduction. Cell. 80:1995;213-223.
4. Pawson T., Schlessinger J. SH2 and SH3 domains. Curr Biol. 3:1993;434-442.
5. Soriano P. Abnormal kidney development and hematological disorders in PDGF β-receptor mutant mice. Genes & Dev. 8:1994;1888-1896.
6. Boström H., Willetts K., Pekny M., Levéen P., Lindahl P., Hedstrand H., Pekna M., Hellström M., Gebre-Medhin S., Schalling M., Nilsson M., Kurland S., Törnell J., Heath J.K., Betsholtz C. PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis. Cell. 85:1996;863-873.
7. Lindahl P., Johansson B.R., Levéen P., Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science. 277:1997;242-245.
8. Westermark B., Heldin C.-H. Platelet-derived growth factor in autocrine transformation. Cancer Res. 51:1991;5087-5092.
9. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature. 362:1993;801-809.
10. Ferns G.A.A., Raines E.W., Sprugel K.H., Motani A.S., Reidy M.A., Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science. 253:1991;1129-1132.
11. Lindner V., Reidy M.A. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci USA. 88:1991;3739-3743.
12. Majesky M.W., Reidy M.A., Bowen-Pope D.F., Hart C.E., Wilcox J.N., Schwartz S.M. PDGF ligand and receptor gene expression during repair of arterial injury. J Cell Biol. 111:1990;2149-2158.
13. Knachigian L.M., Lindner V., Williams A.J., Collins T. Egr-1-induced endothelial gene expression: A common theme in vascular injury. Science. 271:1996;1427-1431.
14. Uchida K., Sasahara M., Morigami N., Hazama F., Kinoshita M. Expression of platelet-derived growth factor B-chain in neointimal smooth muscle cells of balloon injured rabbit femoral arteries. Atherosclerosis. 124:1996;9-23.
15. Jawien A., Bowen-Pope D.F., Lindner V., Schwartz S.M., Clowes A.W. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of angioplasty. J Clin Invest. 89:1992;507-511.
16. Rutherford C., Martin W., Salame M., Carrier M., Änggård E., Ferns G. Substantial inhibition of neo-intimal response to balloon injury in the rat carotid artery using a combination of antibodies to platelet-derived growth factor-BB and basic fibroblast growth factor. Atherosclerosis. 130:1997;45-51.
17. Sirois M.G., Simons M., Edelman E.R. Antisense oligonucleotide inhibition of PDGFR-β receptor subunit expression directs suppression of intimal thickening. Circulation. 95:1997;669-676.
18. Kovalenko M., Gazit A., Böhmer A., Rorsman C., Rönnstrand L., Heldin C.-H., Waltenberger J., Böhmer F.-D., Levitzki A. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res. 54:1994;6106-6114.
19. Dolle R.E., Dunn J.A., Bobko M., Singh B., Kuster J.E., Baizman E., Harris A.L., Sawutz D.G., Miller D., Wang S., Faltynek C.R., Xie W., Sarup J., Bode D.C., Pagani E.D., Silver P.J. 5,7-dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular β-type platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 37:1994;2627-2629.
20. Maguire M.P., Sheets K.R., McVety K., Spada A.P., Zilberstein A. A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 37:1994;2129-2137.
21. Buchdunger E., Zimmerman J., Mett H., Meyer T., Müller M., Regenass U., Lydon N.B. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci USA. 92:1995;2558-2562.
22. Sawutz D.G., Bode D.C., Briggs M., Reid J.R., Canniff P., Caldwell L., Faltynek C.R., Miller D., Dunne J.A., de Garavilla L., Guiles J.W., Weigelt C., Michne W., Trearurywala A.M., Silver P.J. In vitro characterization of a novel series of platelet-derived growth factor receptor tyrosine kinase inhibitors. Biochem Pharmacol. 51:1996;1631-1638.
23. Rothman A., Kulik T.J., Taubman M.B., Berk B.C., Smith C.W.J., Nadal-Ginard B. Development and characterization of a cloned rat pulmonary arterial smooth muscle cell line that maintains differentiated properties through multiple subcultures. Circulation. 86:1992;1977-1986.
24. Claesson-Welsh L., Eriksson A., Morén A., Severinsson L., Ek B., Östman A., Betsholtz C., Heldin C.-H. cDNA cloning and expression of a human platelet-derived growth factor (PDGF) receptor specific for B-chain-containing PDGF molecules. Mol Cell Biol. 8:1988;3476-3486.
25. Coughlin S.R., Barr P.J., Cousens L.S., Fretto L.J., Williams L.T. Acidic and basic fibroblast growth factors stimulate tyrosine kinase activity in vivo. J Biol Chem. 263:1988;988-993.
26. Fry D.W., Kraker A.J., McMichael A., Ambroso L.A., Nelson J.M., Leopold W.R., Connors R.W., Bridges A.J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science. 265:1994;1093-1095.
27. Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S., Itoh N., Shibuya M., Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem. 262:1987;5592-5595.
28. Mohammadi M., McMahon G., Sun L., Tang C., Hirth P., Yeh B.K., Hubbard S.R., Schlessinger J. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science. 276:1997;955-960.
29. Herrera R., Lebwohl D., Garcia de Herreros A., Kallen R.G., Rosen O.M. Synthesis, purification, and characterization of the cytoplasmic domain of the human insulin receptor using a baculovirus expression system. J Biol Chem. 263:1988;5560-5568.
30. Wedegaertner P.B., Gill G.N. Activation of the purified protein tyrosine kinase domain of the epidermal growth factor receptor. J Biol Chem. 264:1989;11346-11353.
31. Hubbard S.R., Wei L., Ellis L., Hendrickson W.A. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature. 372:1994;746-754.
32. Kelly J.D., Haldeman B.A., Grant F.J., Murray M.J., Seifert R.A., Bowen-Pope D.F., Cooper J.A., Kazlauskas A. Platelet-derived growth factor (PDGF) stimulates PDGF receptor subunit dimerization and intersubunit trans-phosphorylation. J Biol Chem. 266:1991;8987-8992.
33. Rönstrand L., Terracio L., Claesson-Welsh L., Heldin C.-H., Rubin K. Characterization of two monoclonal antibodies reactive with the external domain of the platelet-derived growth factor receptor. J Biol Chem. 263:1988;10429-10435.
34. Jensen R.A., Beeler J.F., Heidaran M.A., LaRochelle W.J. Characterization of baculovirus-expressed human α and β platelet-derived growth factor receptors. Biochemistry. 31:1992;10887-10892.
35. Herren B., Rooney B., Weyer K.A., Iberg N., Schmid G., Pech M. Dimerization of extracellular domains of platelet-derived growth factor receptors: A revised model of receptor-ligand interaction. J Biol Chem. 268:1993;15088-15095.
36. Uren A., Yu J.C., Karcaaltincaba M., Pierce J.H., Heidaran M.A. Oncogenic activation of the αPDGFR defines a domain that negatively regulates receptor dimerization. Oncogene. 14:1997;157-162.